Spots Global Cancer Trial Database for myeloid malignancy
Every month we try and update this database with for myeloid malignancy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pre-myeloid Cancer and Bone Marrow Failure Clinic Study | NCT02958462 | Myeloid Maligna... Inherited Bone ... Clonal Expansio... Cytopenia Bone Marrow Fai... Clonal Cytopeni... Clonal Hematopo... Hematologic Neo... Hematopoietic a... Hereditary Neop... Idiopathic Cyto... Idiopathic Dysp... Low Risk Myelod... | Biospecimen Col... Bone Marrow Bio... Punch Biopsy Buccal Swab Clinical Evalua... Genetic Counsel... Quality-of-Life... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. | NCT05841771 | Hypomethylating... Venetoclax Myeloid Maligna... | Venetoclax Azacitidine or ... | 18 Years - 70 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | |
| Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations | NCT04906031 | Myelodysplastic... Acute Myeloid L... Myeloid Maligna... Temperature-Sen... Sodium Stiboglu... P53 Mutation | Sodium stiboglu... | 18 Years - 75 Years | First Affiliated Hospital of Jinan University | |
| Pre-myeloid Cancer and Bone Marrow Failure Clinic Study | NCT02958462 | Myeloid Maligna... Inherited Bone ... Clonal Expansio... Cytopenia Bone Marrow Fai... Clonal Cytopeni... Clonal Hematopo... Hematologic Neo... Hematopoietic a... Hereditary Neop... Idiopathic Cyto... Idiopathic Dysp... Low Risk Myelod... | Biospecimen Col... Bone Marrow Bio... Punch Biopsy Buccal Swab Clinical Evalua... Genetic Counsel... Quality-of-Life... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant | NCT03850418 | Myeloid Maligna... | azacitidine | 18 Years - 75 Years | Henry Ford Health System | |
| Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients | NCT06090513 | Advanced Cancer Solid Tumor, Ad... Myeloid Maligna... | Comprehensive G... limited genetic... | 18 Years - | Bien-Willner Physicians Group PA | |
| A Study of GLB-001 in Patients With Myeloid Malignancies | NCT06378437 | Polycythemia Ve... Essential Throm... Myelofibrosis Myelodysplastic... Acute Myeloid L... Myeloid Maligna... | GLB-001 | 18 Years - | Hangzhou GluBio Pharmaceutical Co., Ltd. | |
| Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation | NCT01596699 | Myeloid Maligna... Bone Marrow Fai... Transfusion-dep... Congenital Immu... Metabolic Disea... Severe Immune D... | Alemtuzumab Busulfan Fludarabine Clofarabine | 3 Months - 30 Years | University of California, San Francisco | |
| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | NCT05455294 | Myeloid Maligna... Myelodysplastic... Myelofibrosis Acute Myeloid L... Myeloproliferat... | Navitoclax Venetoclax Decitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. | NCT05841771 | Hypomethylating... Venetoclax Myeloid Maligna... | Venetoclax Azacitidine or ... | 18 Years - 70 Years | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | |
| Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS | NCT03855371 | P53 Mutation Myeloid Maligna... MDS Aml | Decitabine Arsenic Trioxid... | 18 Years - 75 Years | Ruijin Hospital | |
| APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies | NCT04214860 | Myeloid Maligna... | APR-246 Venetoclax Azacitidine | 18 Years - | Aprea Therapeutics | |
| Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients | NCT06090513 | Advanced Cancer Solid Tumor, Ad... Myeloid Maligna... | Comprehensive G... limited genetic... | 18 Years - | Bien-Willner Physicians Group PA | |
| Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | NCT05583175 | Leukemia, Myelo... MDS Hematopoietic S... Myeloid Maligna... | Venetoclax plus... | 55 Years - | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
